Department of Veterinary Medicine, Institute of Pharmacology and Toxicology, Freie Universität Berlin, Koserstr. 20, 14195 Berlin, Germany.
J Neural Transm (Vienna). 2010 Jun;117(6):747-57. doi: 10.1007/s00702-010-0410-y. Epub 2010 May 9.
The pathophysiology of idiopathic dystonias is still unknown, but it is regarded as a basal ganglia disorder. Previous experiments in the dt(sz) hamster, a model of primary paroxysmal dystonia, demonstrated reduced discharge rates and an abnormal pattern within the entopeduncular nucleus (EPN), a basal ganglia output structure. To clarify if this is based on abnormal gamma-aminobutyric acid(GABA)ergic or glutamatergic input, microinjections into the EPN were done in mutant hamsters in the present study. The GABA(A) receptor antagonists pentylenetetrazole and bicuculline exerted moderate antidystonic effects, while previous systemic administrations worsened dystonia in the dt(sz) mutant. GABA-potentiating drugs, i.e., the GABA(A) receptor agonist muscimol and the GABA transporter inhibitor 1,2,5,6-tetrahydro-1-[2-[[(diphenylmethylene)amino]oxy]ethyl]-3-pyridinecarboxy-lic acid (NNC-711), which are known to improve dystonia after systemic treatment in mutant hamsters, did not exert significant effects after EPN injections, but NNC-711 tended to increase the severity at the highest dose (2.5 ng bilateral). The NMDA receptor antagonist D(-)-2-amino-5-phosphopentanoic acid (AP-5) retarded the onset of a dystonic attack. However, this effect was not dose dependent and the AMPA receptor antagonist 2,3-dihydroxy-6-nitro-7-sulfamoylbenzol(f)quinoxaline (NBQX) alone or in combination with AP-5 and NNC-711, also failed to show any effects on dystonia. The present data do not provide clear evidence for an enhanced striatal GABAergic input or a reduced glutamatergic activation of the EPN via the subthalamic nucleus, i.e., more pronounced antidystonic effects of GABA(A) receptor antagonists and stronger prodystonic effects of GABAmimetics and glutamate receptor antagonists were expected. Nevertheless, previously found changes in entopeduncular activity probably play a critical pathophysiological role in dystonic hamsters.
特发性肌张力障碍的病理生理学仍然未知,但被认为是基底节障碍。先前在原发性阵发性肌张力障碍模型 dt(sz)仓鼠中的实验表明,在苍白球外核(EPN)中放电率降低且模式异常,EPN 是基底节的输出结构。为了阐明这是否基于异常的γ-氨基丁酸(GABA)能或谷氨酸能输入,本研究在突变仓鼠中进行了 EPN 内微注射。GABA(A)受体拮抗剂戊四氮和荷包牡丹碱发挥了适度的抗痉挛作用,而先前的全身给药在 dt(sz)突变体中加重了肌张力障碍。GABA 增强药物,即 GABA(A)受体激动剂 muscimol 和 GABA 转运体抑制剂 1,2,5,6-四氢-1-[2-[[(二苯基亚甲基)氨基]氧基]乙基]-3-吡啶羧酸(NNC-711),已知在突变仓鼠中全身治疗后可改善肌张力障碍,在 EPN 注射后没有显著作用,但 NNC-711 在最高剂量(双侧 2.5ng)时趋于增加严重程度。NMDA 受体拮抗剂 D(-)-2-氨基-5-磷戊酸(AP-5)延迟了痉挛发作的开始。然而,这种作用不是剂量依赖性的,而 AMPA 受体拮抗剂 2,3-二羟基-6-硝基-7-磺酰胺基苯并[f]喹喔啉(NBQX)单独或与 AP-5 和 NNC-711 联合使用,也未能对肌张力障碍产生任何影响。目前的数据没有提供明确的证据表明苍白球外核通过丘脑底核的 GABA 能传入增强或谷氨酸能激活减少,即 GABA(A)受体拮抗剂的抗痉挛作用更强,GABA 模拟物和谷氨酸受体拮抗剂的促痉挛作用更强。然而,先前发现的苍白球外核活动的变化可能在痉挛性仓鼠中起着关键的病理生理作用。